申请人:Adir et Compagnie
公开号:US06245916B1
公开(公告)日:2001-06-12
Compound of formula (I):
wherein:
n is 0 or 1,
W represents —CO— or S(O)q and q is 0, 1 or 2,
G represents a G1, G2, G3 or G4 group as defined in the description,
Z represents alkyl, aryl, heteroaryl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkenyl, heteroarylalkynyl or heteroarylalkyl each optionally substituted.
A represents a grouping selected from —A2—, —A1—A2—, —A2—A1— and —A1—A2—A1— wherein A1 is alkylene and A2 represents phenylene, cycloalkylene, naphthylene or heteroarylene each optionally substituted,
R represents hydrogen, alkyl, aryl, heteroaryl, arylalkyl arylalkenyl, arylalkynyl, heteroarylakenyl, heteroarylalkynyl or heteroarylalkenyl each optionally substituted,
R1 represents alkyl, aryl, heteroary, arylalkyl arylalkenyl, arylalkynyl, heteroarylalkenyl, heteroarylalkynyl or heteroarylalkyl each optionally substituted, and
medicinal products containing the same which are useful as Neuropeptide Y receptor ligands.
化合物的化学式(I):其中n为0或1,W代表—CO—或S(O)q,q为0、1或2,G代表描述中定义的G1、G2、G3或G4基团,Z代表烷基、芳基、杂芳基、芳基烷基、芳基烯基、芳基炔基、杂芳基烯基、杂芳基炔基或杂芳基烷基,每个基团均可选择性地被取代。A代表从—A2—、—A1—A2—、—A2—A1—和—A1—A2—A1—中选择的基团,其中A1为烷基,并且A2代表苯基、环烷基、萘基或杂芳基,每个基团均可选择性地被取代,R代表氢、烷基、芳基、杂芳基、芳基烷基、芳基烯基、芳基炔基、杂芳基烯基、杂芳基炔基或杂芳基烷基,每个基团均可选择性地被取代,R1代表烷基、芳基、杂芳基、芳基烷基、芳基烯基、芳基炔基、杂芳基烯基、杂芳基炔基或杂芳基烷基,每个基团均可选择性地被取代,以及含有这些化合物的药品,这些药品可作为神经肽Y受体配体。